<DOC>
	<DOC>NCT02397707</DOC>
	<brief_summary>This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single dose of GS-9857 in adults with normal and impaired hepatic function. Adults in the healthy control group will be matched to adults with impaired hepatic function by gender, age (± 10 years), and body mass index (± 15%).</brief_summary>
	<brief_title>Pharmacokinetics of GS-9857 in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment</brief_title>
	<detailed_description />
	<criteria>All individuals: Screening laboratory values within defined thresholds for group Use of two effective contraception methods if female of childbearing potential or sexually active male For individuals with moderate hepatic impairment: Diagnosis of chronic (&gt; 6 months) hepatic impairment Score on the ChildPughTurcotte (CPT) scale of 79 at screening (Child Pugh Class B). For individuals with severe hepatic impairment: Diagnosis of chronic (&gt; 6 months) hepatic impairment Score on the CPT scale of 1015 at screening (Child Pugh Class C) For individuals with normal hepatic function: Hepatitis C Virus (HCV) antibody and hepatitis B surface antigen negative All individuals: Pregnant or nursing female or male with pregnant female partner HIV infection History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol For individuals with moderate or severe hepatic impairment: Active HCV infection Current hepatic encephalopathy Variceal bleeding in the last 6 months unless banded Prior placement of a portosystemic shunt History of hepatorenal or hepatopulmonary syndrome Spontaneous bacterial peritonitis currently or within the last 6 months Hospitalization within the last 2 months related to cirrhosis Confirmed hypotension Suspicion of hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>